Summary

Growth Hormone Deficiency Market – Scope of Report
TMR’s report on the global growth hormone deficiency market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global growth hormone deficiency market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global growth hormone deficiency market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the growth hormone deficiency market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global growth hormone deficiency market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global growth hormone deficiency market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global growth hormone deficiency market.

The report delves into the competitive landscape of the global growth hormone deficiency market. Key players operating in the global growth hormone deficiency market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global growth hormone deficiency market profiled in this report.

Key Questions Answered in Global growth hormone deficiency Market Report
• What is the sales/revenue generated by growth hormone deficiency across all regions during the forecast period?
• What are the opportunities in the global growth hormone deficiency market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Growth Hormone Deficiency Market – Research Objectives and Research Approach
The comprehensive report on the global growth hormone deficiency market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global growth hormone deficiency market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global growth hormone deficiency market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Growth Hormone Deficiency Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Growth Hormone Deficiency Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Growth Hormone Deficiency Market Analysis and Forecast, by Treatment Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2020-2034
6.3.1. Therapeutic Treatment
6.3.1.1. Norditropin
6.3.1.2. Genotropin
6.3.1.3. Humatrope
6.3.1.4. Saizen
6.3.1.5. Others (Omnitrope, etc.)
6.3.2. Recombinant Human Growth Hormone
6.3.3. Human Pituitary Gland Extracts
6.3.4. Surgery
6.4. Market Attractiveness, by Treatment Type
7. Global Growth Hormone Deficiency Market Analysis and Forecast, by Disease Indication
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Indication, 2020-2034
7.3.1. Pediatric Growth Hormone Deficiency
7.3.2. Idiopathic Short Stature
7.3.3. Small for Gestational Age
7.3.4. Turner Syndrome
7.3.5. Adult Growth Hormone Deficiency
7.3.6. Others (Prader-Willi Syndrome, etc.)
7.3.7. 7.4 Market Attractiveness, by Disease Indication
8. Global Growth Hormone Deficiency Market Analysis and Forecast, by Route of Administration
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2020-2034
8.3.1. Subcutaneous
8.3.2. Intramuscular
8.3.3. Intravenous
8.4. Market Attractiveness, by Route of Administration
9. Global Growth Hormone Deficiency Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2020-2034
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness, by Distribution Channel
10. Global Growth Hormone Deficiency Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Growth Hormone Deficiency Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2020-2034
11.2.1. Therapeutic Treatment
11.2.1.1. Norditropin
11.2.1.2. Genotropin
11.2.1.3. Humatrope
11.2.1.4. Saizen
11.2.1.5. Others (Omnitrope, etc.)
11.2.2. Recombinant Human Growth Hormone
11.2.3. Human Pituitary Gland Extracts
11.2.4. Surgery
11.3. Market Attractiveness, by Treatment Type
11.4. Market Value Forecast, by Disease Indication, 2020-2034
11.4.1. Pediatric Growth Hormone Deficiency
11.4.2. Idiopathic Short Stature
11.4.3. Small for Gestational Age
11.4.4. Turner Syndrome
11.4.5. Adult Growth Hormone Deficiency
11.4.6. Others (Prader-Willi Syndrome, etc.)
11.5. Market Attractiveness, by Disease Indication
11.6. Market Value Forecast, by Route of Administration, 2020-2034
11.6.1. Subcutaneous
11.6.2. Intramuscular
11.6.3. Intravenous
11.7. Market Attractiveness, by Route of Administration
11.8. Market Value Forecast, by Distribution Channel, 2020-2034
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Online Pharmacies
11.9. Market Attractiveness, by Distribution Channel
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Treatment Type
11.11.2. By Disease Indication
11.11.3. By Route of Administration
11.11.4. By Distribution Channel
11.11.5. By Country
12. Europe Growth Hormone Deficiency Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2020-2034
12.2.1. Therapeutic Treatment
12.2.1.1. Norditropin
12.2.1.2. Genotropin
12.2.1.3. Humatrope
12.2.1.4. Saizen
12.2.1.5. Others (Omnitrope, etc.)
12.2.2. Recombinant Human Growth Hormone
12.2.3. Human Pituitary Gland Extracts
12.2.4. Surgery
12.3. Market Attractiveness, by Treatment Type
12.4. Market Value Forecast, by Disease Indication, 2020-2034
12.4.1. Pediatric Growth Hormone Deficiency
12.4.2. Idiopathic Short Stature
12.4.3. Small for Gestational Age
12.4.4. Turner Syndrome
12.4.5. Adult Growth Hormone Deficiency
12.4.6. Others (Prader-Willi Syndrome, etc.)
12.5. Market Attractiveness, by Disease Indication
12.6. Market Value Forecast, by Route of Administration, 2020-2034
12.6.1. Subcutaneous
12.6.2. Intramuscular
12.6.3. Intravenous
12.7. Market Attractiveness, by Route of Administration
12.8. Market Value Forecast, by Distribution Channel, 2020-2034
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Online Pharmacies
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Treatment Type
12.11.2. By Disease Indication
12.11.3. By Route of Administration
12.11.4. By Distribution Channel
12.11.5. By Country/Sub-region
13. Asia Pacific Growth Hormone Deficiency Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2020-2034
13.2.1. Therapeutic Treatment
13.2.1.1. Norditropin
13.2.1.2. Genotropin
13.2.1.3. Humatrope
13.2.1.4. Saizen
13.2.1.5. Others (Omnitrope, etc.)
13.2.2. Recombinant Human Growth Hormone
13.2.3. Human Pituitary Gland Extracts
13.2.4. Surgery
13.3. Market Attractiveness, by Treatment Type
13.4. Market Value Forecast, by Disease Indication, 2020-2034
13.4.1. Pediatric Growth Hormone Deficiency
13.4.2. Idiopathic Short Stature
13.4.3. Small for Gestational Age
13.4.4. Turner Syndrome
13.4.5. Adult Growth Hormone Deficiency
13.4.6. Others (Prader-Willi Syndrome, etc.)
13.5. Market Attractiveness, by Disease Indication
13.6. Market Value Forecast, by Route of Administration, 2020-2034
13.6.1. Subcutaneous
13.6.2. Intramuscular
13.6.3. Intravenous
13.7. Market Attractiveness, by Route of Administration
13.8. Market Value Forecast, by Distribution Channel, 2020-2034
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Online Pharmacies
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Treatment Type
13.11.2. By Disease Indication
13.11.3. By Route of Administration
13.11.4. By Distribution Channel
13.11.5. By Country/Sub-region
14. Latin America Growth Hormone Deficiency Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment Type, 2020-2034
14.2.1. Therapeutic Treatment
14.2.1.1. Norditropin
14.2.1.2. Genotropin
14.2.1.3. Humatrope
14.2.1.4. Saizen
14.2.1.5. Others (Omnitrope, etc.)
14.2.2. Recombinant Human Growth Hormone
14.2.3. Human Pituitary Gland Extracts
14.2.4. Surgery
14.3. Market Attractiveness, by Treatment Type
14.4. Market Value Forecast, by Disease Indication, 2020-2034
14.4.1. Pediatric Growth Hormone Deficiency
14.4.2. Idiopathic Short Stature
14.4.3. Small for Gestational Age
14.4.4. Turner Syndrome
14.4.5. Adult Growth Hormone Deficiency
14.4.6. Others (Prader-Willi Syndrome, etc.)
14.5. Market Attractiveness, by Disease Indication
14.6. Market Value Forecast, by Route of Administration, 2020-2034
14.6.1. Subcutaneous
14.6.2. Intramuscular
14.6.3. Intravenous
14.7. Market Attractiveness, by Route of Administration
14.8. Market Value Forecast, by Distribution Channel, 2020-2034
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Online Pharmacies
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Treatment Type
14.11.2. By Disease Indication
14.11.3. By Route of Administration
14.11.4. By Distribution Channel
14.11.5. By Country/Sub-region
15. Middle East & Africa Growth Hormone Deficiency Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Treatment Type, 2020-2034
15.2.1. Therapeutic Treatment
15.2.1.1. Norditropin
15.2.1.2. Genotropin
15.2.1.3. Humatrope
15.2.1.4. Saizen
15.2.1.5. Others (Omnitrope, etc.)
15.2.2. Recombinant Human Growth Hormone
15.2.3. Human Pituitary Gland Extracts
15.2.4. Surgery
15.3. Market Attractiveness, by Treatment Type
15.4. Market Value Forecast, by Disease Indication, 2020-2034
15.4.1. Pediatric Growth Hormone Deficiency
15.4.2. Idiopathic Short Stature
15.4.3. Small for Gestational Age
15.4.4. Turner Syndrome
15.4.5. Adult Growth Hormone Deficiency
15.4.6. Others (Prader-Willi Syndrome, etc.)
15.5. Market Attractiveness, by Disease Indication
15.6. Market Value Forecast, by Route of Administration, 2020-2034
15.6.1. Subcutaneous
15.6.2. Intramuscular
15.6.3. Intravenous
15.7. Market Attractiveness, by Route of Administration
15.8. Market Value Forecast, by Distribution Channel, 2020-2034
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Online Pharmacies
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Treatment Type
15.11.2. By Disease Indication
15.11.3. By Route of Administration
15.11.4. By Distribution Channel
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Novo Nordisk A/S
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Pfizer Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Merck KGaA
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Eli Lilly and Company
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Novartis AG
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. F. Hoffmann-La Roche AG
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Ipsen Pharma
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Ferring Pharmaceuticals
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Anhui Anke Biotechnology (Group) Co., Ltd.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Zhongshan Sinobioway Hygene Biomedicine Co., Ltd.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Others
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview